|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu
H, Chen L, Xu J and Lin Z: High CXC chemokine receptor 4 expression
is an adverse prognostic factor in patients with clear-cell renal
cell carcinoma. Br J Cancer. 110:2261–2268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stewart GD, O'Mahony FC, Powles T, Riddick
AC, Harrison DJ and Faratian D: What can molecular pathology
contribute to the management of renal cell carcinoma? Nat Rev Urol.
8:255–265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karakiewicz PI, Briganti A, Chun FK, Trinh
QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J,
Mulders PF, et al: Multi-institutional validation of a new renal
cancer-specific survival nomogram. J Clin Oncol. 25:1316–1322.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lam JS, Leppert JT, Figlin RA and
Belldegrun AS: Role of molecular markers in the diagnosis and
therapy of renal cell carcinoma. Urology. 66(Suppl 5): S1–S9. 2005.
View Article : Google Scholar
|
|
6
|
Libura J, Drukala J, Majka M, Tomescu O,
Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG,
Janowska-Wieczorek A, et al: CXCR4-SDF-1 signaling is active in
rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and
adhesion. Blood. 100:2597–2606. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Phillips RJ, Burdick MD, Lutz M, Belperio
JA, Keane MP and Strieter RM: The stromal derived
factor-1/CXCL12-CXC chemokine receptor 4 biological axis in
non-small cell lung cancer metastases. Am J Respir Crit Care Med.
167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taichman RS, Cooper C, Keller ET, Pienta
KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived
factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
|
|
9
|
Hall JM and Korach KS: Stromal
cell-derived factor 1, a novel target of estrogen receptor action,
mediates the mitogenic effects of estradiol in ovarian and breast
cancer cells. Mol Endocrinol. 17:792–803. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaifi JT, Yekebas EF, Schurr P, Obonyo D,
Wachowiak R, Busch P, Heinecke A, Pantel K and Izbicki JR:
Tumor-cell homing to lymph nodes and bone marrow and CXCR4
expression in esophageal cancer. J Natl Cancer Inst. 97:1840–1847.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SY, Lee CH, Midura BV, Yeung C,
Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, et al:
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the
development of murine pulmonary metastases. Clin Exp Metastasis.
25:201–211. 2008. View Article : Google Scholar
|
|
12
|
Zagzag D, Krishnamachary B, Yee H, Okuyama
H, Chiriboga L, Ali MA, Melamed J and Semenza GL: Stromal
cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma
and clear cell-renal cell carcinoma: Von Hippel-Lindau
loss-of-function induces expression of a ligand and its receptor.
Cancer Res. 65:6178–6188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
D'Alterio C, Cindolo L, Portella L,
Polimeno M, Consales C, Riccio A, Cioffi M, Franco R, Chiodini P,
Cartenì G, et al: Differential role of CD133 and CXCR4 in renal
cell carcinoma. Cell Cycle. 9:4492–4500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho KS, Yoon SJ, Lee JY, Cho NH, Choi YD,
Song YS and Hong SJ: Inhibition of tumor growth and
histopathological changes following treatment with a chemokine
receptor CXCR4 antagonist in a prostate cancer xenograft model.
Oncol Lett. 6:933–938. 2013.PubMed/NCBI
|
|
15
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Na IK, Scheibenbogen C, Adam C, Stroux A,
Ghadjar P, Thiel E, Keilholz U and Coupland SE: Nuclear expression
of CXCR4 in tumor cells of non-small cell lung cancer is correlated
with lymph node metastasis. Hum Pathol. 39:1751–1755. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spano JP, Andre F, Morat L, Sabatier L,
Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, et
al: Chemokine receptor CXCR4 and early-stage non-small cell lung
cancer: Pattern of expression and correlation with outcome. Ann
Oncol. 15:613–617. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masuda T, Nakashima Y, Ando K, Yoshinaga
K, Saeki H, Oki E, Morita M, Oda Y and Maehara Y: Nuclear
expression of chemokine receptor CXCR4 indicates poorer prognosis
in gastric cancer. Anticancer Res. 34:6397–6403. 2014.PubMed/NCBI
|
|
19
|
Wagner PL, Hyjek E, Vazquez MF, Meherally
D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, et al:
CXCL12 and CXCR4 in adenocarcinoma of the lung: Association with
metastasis and survival. J Thorac Cardiovasc Surg. 137:615–621.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshitake N, Fukui H, Yamagishi H,
Sekikawa A, Fujii S, Tomita S, Ichikawa K, Imura J, Hiraishi H and
Fujimori T: Expression of SDF-1 alpha and nuclear CXCR4 predicts
lymph node metastasis in colorectal cancer. Br J Cancer.
98:1682–1689. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Speetjens FM, Liefers GJ, Korbee CJ,
Mesker WE, van de Velde CJ, van Vlierberghe RL, Morreau H,
Tollenaar RA and Kuppen PJ: Nuclear localization of CXCR4
determines prognosis for colorectal cancer patients. Cancer
Microenviron. 2:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Chen W, Gao L, Yang Q, Liu B, Wu
Z, Wang Y and Sun Y: High expression of CXCR4, CXCR7 and SDF-1
predicts poor survival in renal cell carcinoma. World J Surg Oncol.
10:2122012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang LH, Liu Q, Xu B, Chen W, Yang Q, Wang
ZX and Sun YH: Identification of nuclear localization sequence of
CXCR4 in renal cell carcinoma by constructing expression plasmids
of different deletants. Plasmid. 63:68–72. 2010. View Article : Google Scholar
|
|
24
|
Ma QH, Futagawa T, Yang WL, Jiang XD, Zeng
L, Takeda Y, Xu RX, Bagnard D, Schachner M, Furley AJ, et al: A
TAG1-APP signalling pathway through Fe65 negatively modulates
neurogenesis. Nat Cell Biol. 10:283–294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lyu J, Yamamoto V and Lu W: Cleavage of
the Wnt receptor Ryk regulates neuronal differentiation during
cortical neurogenesis. Dev Cell. 15:773–780. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carpenter G and Liao HJ: Trafficking of
receptor tyrosine kinases to the nucleus. Exp Cell Res.
315:1556–1566. 2009. View Article : Google Scholar :
|
|
27
|
Don-Salu-Hewage AS, Chan SY, McAndrews KM,
Chetram MA, Dawson MR, Bethea DA and Hinton CV: Cysteine (C)-x-C
receptor 4 undergoes transportin 1-dependent nuclear localization
and remains functional at the nucleus of metastatic prostate cancer
cells. PLoS One. 8:e571942013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan L, Cai Q and Xu Y: The ubiquitin-CXCR4
axis plays an important role in acute lung infection-enhanced lung
tumor metastasis. Clin Cancer Res. 19:4706–4716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tripathi A, Davis JD, Staren DM, Volkman
BF and Majetschak M: CXC chemokine receptor 4 signaling upon
co-activation with stromal cell-derived factor-1α and ubiquitin.
Cytokine. 65:121–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burgess A, Buck M, Krauer K and Sculley T:
Nuclear localization of the Epstein-Barr virus EBNA3B protein. J
Gen Virol. 87:789–793. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ren M, Qiu S, Venglat P, Xiang D, Feng L,
Selvaraj G and Datla R: Target of rapamycin regulates development
and ribosomal RNA expression through kinase domain in Arabidopsis.
Plant Physiol. 155:1367–1382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao FL and Guo W: Expression of stromal
derived factor-1 (SDF-1) and chemokine receptor (CXCR4) in bone
metastasis of renal carcinoma. Mol Biol Rep. 38:1039–1045. 2011.
View Article : Google Scholar
|
|
33
|
Wang L, Wang Z, Yang B, Yang Q, Wang L and
Sun Y: CXCR4 nuclear localization follows binding of its ligand
SDF-1 and occurs in metastatic but not primary renal cell
carcinoma. Oncol Rep. 22:1333–1339. 2009.PubMed/NCBI
|
|
34
|
Almofti A, Uchida D, Begum NM, Tomizuka Y,
Iga H, Yoshida H and Sato M: The clinicopathological significance
of the expression of CXCR4 protein in oral squamous cell carcinoma.
Int J Oncol. 25:65–71. 2004.PubMed/NCBI
|
|
35
|
Vicente-Manzanares M, Ma X, Adelstein RS
and Horwitz AR: Non-muscle myosin II takes centre stage in cell
adhesion and migration. Nat Rev Mol Cell Biol. 10:778–790. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aguilar-Cuenca R, Juanes-García A and
Vicente-Manzanares M: Myosin II in mechanotransduction: Master and
commander of cell migration, morphogenesis, and cancer. Cell Mol
Life Sci. 71:479–492. 2014. View Article : Google Scholar
|
|
37
|
Carpenter G and Red Brewer M: EpCAM:
Another surface-to-nucleus missile. Cancer Cell. 15:165–166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hindman B, Goeckeler Z, Sierros K and
Wysolmerski R: Non-muscle myosin II isoforms have different
functions in matrix rearrangement by MDA-MB-231 cells. PLoS One.
10:e01319202015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Duxbury MS, Ashley SW and Whang EE:
Inhibition of pancreatic adenocarcinoma cellular invasiveness by
blebbistatin: A novel myosin II inhibitor. Biochem Biophys Res
Commun. 313:992–997. 2004. View Article : Google Scholar : PubMed/NCBI
|
